Abiopharma

🔍 Olivo Alicia C (Executive)

Company: NEOGENOMICS INC (NEO)

Report Date: 2025-09-01

Detailed Transactions and Holdings:

• Sold 1,666 shares of Common Stock (Direct)
  Date: 2025-09-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 47,940.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 1,046 shares of Stock Option (Right to Buy) at $19.12 per share (Derivative)
  Date: 2025-09-01 | Code: H | Expires: 2026-09-30 | shares_owned_after: 1,046.00 | Footnotes: F2
• Holds 1,024 shares of Stock Option (Right to Buy) at $27.34 per share (Derivative)
  Date: 2025-09-01 | Code: H | Expires: 2027-05-01 | shares_owned_after: 1,024.00 | Footnotes: F3
• Holds 516 shares of Stock Option (Right to Buy) at $48.99 per share (Derivative)
  Date: 2025-09-01 | Code: H | Expires: 2028-05-01 | shares_owned_after: 516.00 | Footnotes: F4
• Holds 1,117 shares of Stock Option (Right to Buy) at $46.1 per share (Derivative)
  Date: 2025-09-01 | Code: H | Expires: 2028-08-01 | shares_owned_after: 1,117.00 | Footnotes: F5
• Holds 22,222 shares of Stock Option (Right to Buy) at $9.45 per share (Derivative)
  Date: 2025-09-01 | Code: H | Expires: 2029-05-01 | shares_owned_after: 22,222.00 | Footnotes: F6
• Holds 55,332 shares of Stock Option (Right to Buy) at $10.05 per share (Derivative)
  Date: 2025-09-01 | Code: H | Expires: 2029-09-01 | shares_owned_after: 55,332.00 | Footnotes: F7
• Holds 36,508 shares of Stock Option (Right to Buy) at $19.65 per share (Derivative)
  Date: 2025-09-01 | Code: H | Expires: 2030-05-11 | shares_owned_after: 36,508.00 | Footnotes: F8
• Holds 6,503 shares of Restricted Stock Unit (Derivative)
  Date: 2025-09-01 | Code: H | shares_owned_after: 6,503.00 | Footnotes: F9, F10
• Holds 19,508 shares of Performance Stock Unit (Derivative)
  Date: 2025-09-01 | Code: H | Exercise: 2026-05-11 | shares_owned_after: 19,508.00 | Footnotes: F11, F10
• Holds 42,344 shares of Stock Option (Right to Buy) at $16.45 per share (Derivative)
  Date: 2025-09-01 | Code: H | Expires: 2034-02-23 | shares_owned_after: 42,344.00 | Footnotes: F12
• Holds 59,382 shares of Restricted Stock Unit (Derivative)
  Date: 2025-09-01 | Code: H | Exercise: 2026-01-13 | shares_owned_after: 59,382.00 | Footnotes: F10
• Holds 25,330 shares of Performance Stock Unit (Derivative)
  Date: 2025-09-01 | Code: H | Exercise: 2027-02-23 | shares_owned_after: 25,330.00 | Footnotes: F13, F10
• Holds 16,886 shares of Restricted Stock Unit (Derivative)
  Date: 2025-09-01 | Code: H | shares_owned_after: 16,886.00 | Footnotes: F14, F10
• Holds 107,450 shares of Stock Option (Right to Buy) at $13.05 per share (Derivative)
  Date: 2025-09-01 | Code: H | Expires: 2035-02-21 | shares_owned_after: 107,450.00 | Footnotes: F15, F16
• Holds 63,238 shares of Restricted Stock Unit (Derivative)
  Date: 2025-09-01 | Code: H | shares_owned_after: 63,238.00 | Footnotes: F17, F10

Footnotes:

• F1: Shares surrendered to NeoGenomics, Inc. for retirement to satisfy the tax obligations in connection with the September 1, 2025 vesting of restricted stock.
• F2: On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vest ratably over the first four anniversary dates of the grant date.
• F3: On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date.
• F4: On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date.
• F5: On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date.
• F6: On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date.
• F7: On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date.
• F8: On May 11, 2023, Ms. Olivo was granted 36,508 stock options. The options vest ratably over the first three anniversary dates of the grant date.
• F9: On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
• F10: Once vested, the shares of common stock are not subject to expiration.
• F11: On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company.
• F12: On February 23, 2024, Ms. Olivo was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date.
• F13: On February 23, 2024, Ms. Olivo was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
• F14: On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
• F15: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%.
• F16: On February 21, 2025, Ms. Olivo was granted 107,450 stock options. The options vest ratably over the first three anniversary dates of the grant date.
• F17: On February 21, 2025, Ms. Olivo was granted 63,238 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.